SCHEMBL5201507

SCHEMBL5201507

O=C1c2ccccc2C(=O)N1c1ccc2ccc(O)nc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
POLB P06746 1/20 0.37
NR1H3 Q13133 1/20 0.36
SCN2A Q99250 2/20 0.36
HTT P42858 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ALPL P05186 3/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ESR1 P03372 1/20 0.35
AR P10275 1/20 0.35
PIM3 Q86V86 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7329332 0.81 MEN1 (0.42) ALDH1A1KDM4EGAAPOLBHTT
SCHEMBL14336359 0.81 RECQL (0.42) ALDH1A1KDM4EGAAPOLBALPL
SCHEMBL7329911 0.81 ALDH1A1 (0.40) ALDH1A1KDM4EGAAPOLBHTT
SCHEMBL11486646 0.80 ALDH1A1 (0.41) ALDH1A1KMT2A
SCHEMBL11486146 0.79 CA12 (0.40) CA12CA1CA2CA9
SCHEMBL5200701 0.77 KDM4E (0.54) ALDH1A1KDM4EGAAPOLBHTT
SCHEMBL10472405 0.77 POLB (0.37) ALDH1A1KDM4EGAAPOLBNR1H3
SCHEMBL11548784 0.73 HTR1A (0.51) ALDH1A1KDM4EGAAPOLBHTT
SCHEMBL30046397 0.73 HTR1A (0.51) ALDH1A1KDM4EGAAPOLBHTT
SCHEMBL12195998 0.71 POLB (0.47) POLBNR1H3SCN2AHTTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304158-B2 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. (US) 2007-12-04 US disclosed
US-7304158-B2 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. (US) 2007-12-04 US disclosed
US-7304158-B2 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. (US) 2007-12-04 US disclosed
US-20060194830-A1 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. 2006-08-31 US disclosed
US-7057047-B2 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone INDEVUS PHARMACEUTICALS, INC. (US) 2006-06-06 US disclosed
EP-1490363-B1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE INDEVUS PHARMACEUTICALS INC (US) 2006-01-25 EP disclosed
US-20050288322-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone INDEVUS PHARMACEUTICALS, INC. (US) 2005-12-29 US disclosed
US-6949653-B2 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone INDEVUS PHARMACEUTICALS, INC. (US) 2005-09-27 US disclosed
EP-1490363-A1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE Warner-Lambert Company LLC (US) 2004-12-29 EP disclosed
US-20030191315-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone ENDO PHARMACEUTICALS INC. 2003-10-09 US disclosed
WO-2003082870-A1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE WARNER-LAMBERT COMPANY LLC (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288322-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone NT5C3B, NT5C, CYP2J2 ALDH1A1 135/4885KDM4E 3157/4885GAA 3316/4885
US-20030191315-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone NT5C, NT5C3B, UGT8 ALDH1A1 238/4885KDM4E 3343/4885GAA 3060/4885
US-20060194830-A1 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) NT5C, NT5C3B, UGT8 ALDH1A1 272/4885KDM4E 3333/4885GAA 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.